Thyrocare Technologies has reported a robust performance in Q3 FY26, with consolidated revenue rising 18% year-on-year to Rs. 195.53 crore, driven by a 20% surge in its Pathology segment.

Profit After Tax (PAT) after exceptional items jumped 47% to Rs. 27.91 crore, underscoring the company’s focus on profitable growth.

EBITDA also posted impressive growth, climbing 38% YoY to Rs. 57.64 crore. India’s largest diagnostic test volume processor further cemented its leadership by handling 49.6 million tests during the quarter, up 22% year-on-year. Within Pathology, franchise revenue grew 12%, while partnership revenue, including its Pharmeasy collaboration, surged 39% YoY.

The company’s commitment to quality excellence was evident, achieving Six Sigma standards—reducing complaints per million tests to 3.2, down 43% YoY—with an average turnaround time (ATAT) of 3.28 hours. Thyrocare becomes the first diagnostic chain in India to hit this benchmark.

The company also recently onboarded Bollywood icon Madhuri Dixit as brand ambassador to boost awareness of early detection and routine health monitoring.

Commenting on the results, Rahul Guha, MD & CEO of Thyrocare Technologies, said: "We are pleased to report a robust set of results for the quarter. These numbers underscore our continued focus on operational excellence, network expansion, and value-driven diagnostics. As we deepen our presence in underserved regions and scale our franchise and partner channels, we remain committed to delivering high-quality, affordable healthcare services across India.”

Thyrocare’s Q3 performance reinforces its position as a market leader, combining scale, quality, and patient-focused care to drive the future of diagnostics in India.